Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29828983 | 0.86 | MTOR (0.58) | MTORPIK3CA | |
| SCHEMBL4061883 | 0.86 | MTOR (0.58) | MTORPIK3CA | |
| SCHEMBL482077 | 0.80 | MTOR (0.64) | MTORPIK3CAGSK3A | |
| SCHEMBL481964 | 0.78 | MTOR (0.61) | MTORPIK3CAGSK3A | |
| SCHEMBL481672 | 0.78 | MTOR (0.72) | MTORPIK3CAGSK3A | |
| SCHEMBL481803 | 0.77 | MTOR (0.78) | MTORPIK3CAGSK3A | |
| SCHEMBL481397 | 0.76 | MTOR (0.67) | MTORPIK3CAGSK3A | |
| SCHEMBL481448 | 0.75 | MTOR (0.85) | MTORPIK3CAGSK3A | |
| SCHEMBL481512 | 0.75 | MTOR (0.80) | MTORPIK3CAGSK3A | |
| SCHEMBL481586 | 0.75 | MTOR (0.73) | MTORPIK3CAGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | claimed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | claimed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | claimed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | MTOR 73/4885PIK3CA 221/4885GSK3A 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.